USA Change Macroaxis User Registration

Home Portfolios Solutions About Us

More ROI Blog

Overview Mobile PortfolioWidgetsBacktestingToolsetFinancial ContentInvestment Grader

US Market Closed: Feb 8, 03:06 AM 2012

NYSE 8069.71 NASDAQ 2904.08

and more..

sponsered by

Processing
Collecting necessary data for SLXP and TBV...

Asset Comparison and Correlation

View All Portfolios

More Actions
- Select Assests
- Optimize Portfolio
- Suggest Portfolio
- Backtest Watchlist
- Analyze Correlations
- View Transactions
- Check Volatilities
- Import Equities
- Search Equities
- Filter Tops

Salix Pharmaceuticals Ltd. and

Tiens Biotech Group (USA) Inc

Volatility

Matrix

Run Correlation

Diversification

Pay attention

Overlapping area represents amount of risk that can be diversified away by holding Salix Pharmaceuticals Ltd. and Tiens Biotech Group (USA) Inc in the same portfolio (assuming nothing else is changed)

Optimize

Correlation Coefficient

0.0

Parameters

Time Period	1 Month [change]
Direction	Flat
Strength	Insignificant
Accuracy	0.0%
Values	Daily Returns

Suggest

48.43

Intraday

One Month

^0.00

0.00%

SLXP

NASDAQ

Salix Pharmaceuticals Ltd.

P/E	37.25	P/B Ratio	5.96
Market Cap	2.864B	Volume	Not Applicable
Last Close	48.43	Short Ratio	7.80
Last Traded	2/7/2012	Year High	50.28
EBITDA	142.7M	Year Low	25.64
Book Value	8.127	EPS	1.30
PEG Ratio	0.94	High	Not Applicable
Target Price	54.27	Current EPS	1.30
This Year EPS	2.53	Next Year EPS	2.78
Current PE	37.25	This Year PE	19.14
Next Year PE	17.42	Dividend	Not Applicable

Illumina's Board Unanimously Rejects Roche's Offer; Shire Announces FDA ...

BioMedReports (subscription) - 6 hours ago

By Staff and Wire Reports Below is a look at some of the headlines for companies that made news in the healthcare sector on February 7, 2012.

2012-02-07

Salix Pharma Says FDA Grants Priority Review Designation For Crofelemer NDA

NASDAQ - 19 hours ago

(RTTNews.com) - Salix Pharmaceuticals Ltd. (SLXP) announced that the US Food and Drug Administration has granted Priority Review designation for the Company's New Drug Application or NDA for crofelemer 125 mg tablets for the proposed indication for the ...

2012-02-07

Salix Pharmaceuticals Announces FDA Granting of Priority Review Designation ...

MarketWatch (press release) - 20 hours ago

RALEIGH, NC, Feb 07, 2012 (BUSINESS WIRE) -- Salix Pharmaceuticals, Ltd. /quotes/zigman/87125/quotes/nls/slxp SLXP -0.25% today announced that the US Food and Drug Administration (FDA) has granted Priority Review designation for the Company's New Drug ...

2012-02-07